Abstract

Objectives: Embelin has been used in various treatments for skin diseases have excellent efficacy and have beenwidely used in folk remedies. Therefore, we want to observe the possibility of embelin as an additive to cosmetics.Method: The cytotoxicity test was conducted to observe the safety of the component, and the antioxidantforce of the component itself was observed using a DPPH solution. The effects on ROS generation using DCFDAwere observed. We observed the potential as a inhibitor of NO produced by inflammatory reactions andmeasured tyrosinase activity and melanin production to observe the possibility of utilization as skin whitening.Findings: The results of observing the decimals using DPPH showed weak inhibition due to be weaklysuppressed. Antioxidants were observed using Raw 264.7 macrophage. It inhibited ROS production in thecells induced by silica. In particular, production was inhibited on a concentration-dependent basis. As aresult, the embelin has its own antioxidant function, has been shown to act as antioxidant in cells, and itsconcentration has inhibited NO production. Although the tyrosinase activity using L-dopa and L-tyrosine assubstrates did not have any significant effect, melanin production in melanin cells resulted in concentration- dependent suppression.Applications: Based on these results, it was found that embelin was highly antioxidant and was likely to beused as an anti-aging cosmetics ingredient.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.